表紙
市場調査レポート

間質性膀胱炎(膀胱痛症候群):パイプライン製品の分析

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213127
出版日 ページ情報 英文 100 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
間質性膀胱炎(膀胱痛症候群):パイプライン製品の分析 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 100 Pages
概要

間質性膀胱炎は、膀胱痛症候群とも呼ばれる慢性疾患で、膀胱圧、膀胱痛、骨盤痛など、軽度の不快感から激痛まで含まれます。膀胱容量の低下、性交痛、慢性骨盤痛、頻尿、尿意切迫感などの症状が見られます。危険因子は、年齢、性別、慢性疼痛性障害(過敏性腸症候群、線維筋痛症など)です。治療には、非ステロイド性抗炎症薬、抗鬱薬、抗ヒスタミン薬などが含まれます。

当レポートでは、間質性膀胱炎(膀胱痛症候群)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

間質性膀胱炎(膀胱痛症候群)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Astellas Pharma Inc.
  • Kytogenics Pharmaceuticals, Inc.
  • Urigen Pharmaceuticals, Inc.
  • Stem Cell Therapeutics Corp.
  • TARIS BioMedical, Inc.
  • Spherix Incorporated 23
  • Aquinox Pharmaceuticals Inc.
  • Afferent Pharmaceuticals, Inc.
  • Lipella Pharmaceuticals, Inc.
  • Rottapharm|Madaus
  • Qu Biologics Inc.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ASP-3652
  • URG-101
  • AF-219
  • AQX-1125
  • lidocaine
  • LP-08
  • TTI-1612
  • CR-3465
  • SPX-10624258
  • (SPX-106 + D-tagatose)
  • mesalamine
  • NEO-5937
  • GM-0111
  • GM-1111
  • NEO-5024
  • QBECP SSI
  • Antiproliferative Factor Analog For Interstitial Cystitis

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7747IDB

Summary

Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
  • The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interstitial Cystitis (Painful Bladder Syndrome) Overview
  • Therapeutics Development
    • Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview
    • Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis
  • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies
  • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies
  • Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes
  • Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
    • Afferent Pharmaceuticals, Inc.
    • Allergan Plc
    • Aquinox Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • Kytogenics Pharmaceuticals, Inc.
    • Lipella Pharmaceuticals, Inc.
    • MediPost Co., Ltd.
    • Qu Biologics Inc.
    • UCB S.A.
    • Urigen Pharmaceuticals, Inc.
    • UroGen Pharmaceuticals, Ltd.
  • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (heparin + lidocaine) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AF-219 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AQX-1125 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-6294 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cartistem - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LP-08 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mesalamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEO-5024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • onabotulinumtoxinA SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QBECP-SSI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates
  • Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
  • Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
  • Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
      • Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
      • Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
      • Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
      • Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
      • Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results from Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
      • Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
      • Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
      • May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
      • Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2016
  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB S.A., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2016
  • Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2016
  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top